ERBB2 and breast cancer: Even though the cohort was extensively pretreated (76% relapsed following HER2 inhibitor therapy, and 66% had ≥3 prior chemotherapeutic regimens), BAT8001 showed potential efficacy in advanced or metastatic HER2-positive breast cancer.